Fundamental analysis BNR (Burning Rock Biotech Limited)

Updated on 07/20/2026

We analyzed Burning Rock Biotech stock against the 10 quality criteria of Lubin Investment. The company gets a quality score of 4/10, meaning low quality.

Sector: Diagnostics & Research. Listing: US. Current price: 9.07 USD.

Lubin scoring methodology

Burning Rock Biotech Limited (BNR)'s score is calculated automatically from 10 objective financial criteria, with no human intervention or opinion. Each criterion is validated (YES / PARTIAL / NO) based on thresholds drawn from the financial literature (Warren Buffett, Bettin-Mauboussin, Aswath Damodaran). The final score is the sum of validations.

The 10 quantitative criteria analyzed

1. Profitable: positive net margin
2. Growing revenue: revenue growing > 10%/year over 5 years
3. Growing earnings per share: FCF per share adjusted for stock-based compensation, > 10%/year over 5 years
4. Share count under control: stable or declining (net buybacks = value creation for shareholders)
5. Cash profitability: free cash flow margin > 10% of revenue
6. Expanding margins: operating margin widens over 5 years (operating leverage)
7. Return on invested capital: Bettin-Mauboussin Cash ROCE > 15% per year
8. Debt under control: net debt repayable in less than 3 years of free cash flow
9. Earnings converted to cash: free cash flow exceeds accounting net income
10. Net collection period: short or negative cash conversion cycle

Frequently asked questions

Is Burning Rock Biotech a quality stock?

Burning Rock Biotech gets a quality score of 4/10 (low quality), calculated over the 10 Lubin Investment criteria: profitability, revenue and free cash flow growth, share buybacks, margins, debt and return on capital.

How is Burning Rock Biotech's score calculated?

The score is the total of validated criteria (YES / PARTIAL / NO) using thresholds drawn from the financial literature (Warren Buffett, Mauboussin, Aswath Damodaran), automatically and with no human opinion.

Where to see Burning Rock Biotech's full analysis?

The full interactive analysis (10-criteria detail, history, P/FCF valuation, sector comparisons) is available at https://lubin-investment.com/analyse/BNR?lng=en.

Other stocks in the Diagnostics & Research sector

• Medpace Holdings (MEDP) — score 10/10, P/FCF 18.9×
• Veracyte (VCYT) — score 9/10, P/FCF 35.3×
• IDEXX Laboratories (IDXX) — score 8/10, P/FCF 43.4×
• Illumina (ILMN) — score 8/10, P/FCF 34.5×
• Clínica Baviera (CBAV.MC) — score 8/10, P/FCF 19.6×

Go further

👉 See the full interactive analysis of BNR

Other resources : Detailed methodology · All stocks in the Diagnostics & Research sector · Stocks rated 10 out of 10 · Top quality companies · Lubin Investment pricing.